Phase 1 Trial of CXD101 in Patients With Advanced Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the highest dose of CXD101 (a novel histone
deacetylase inhibitor) that can be safely administered to patients with advanced tumours. The
study will also investigate the use of HR23B expression in tumour as a biomarker of response
to treatment with CXD101. Patients with solid tumours, lymphoma and myeloma can be considered
for this study.
Phase:
Phase 1
Details
Lead Sponsor:
Oxford University Hospitals NHS Trust
Collaborators:
Cancer Research UK National Institute for Health Research, United Kingdom University of Oxford